Jared Dummitt is an associate in Cohen Milstein’s Antitrust practice. Jared represents a broad range of individuals and businesses in civil litigation, with a focus on multi-district class actions and antitrust litigation.
Prior to joining Cohen Milstein, Jared was an associate for an internationally renowned litigation law firm, handling both defense and plaintiff-side matters involving class actions, antitrust, intellectual property, and appeals, as well as employment discrimination.
Before entering private practice, Jared clerked for the Honorable Kimba M. Wood of the United States District Court for the Southern District of New York and for the Honorable Michael Daly Hawkins of the United States Court of Appeals for the Ninth Circuit.
Prior to law school, Jared worked as a legal analyst at a highly regarded global disputes and Investigations law firm.
- New York
- Harvard Law School, J.D., cum laude, 2018
- University of Chicago, B.A., 2013
- Law Clerk, the Hon. Kimba M. Wood, U.S. District Court, Southern District of New York (2019 – 2020)
- Law Clerk, the Hon. Michael Daly Hawkins, U.S. Court of Appeals for the Ninth Circuit (2018 – 2019)
Current Cases
In Re Axon VieVu Antitrust Litigation
In Re Axon VieVu Antitrust Litigation (D.N.J.): Cohen Milstein, as Co-Lead Counsel, represents the Mayor and City Council of Baltimore and other municipalities in this consolidated antitrust class action, alleging that Axon unlawfully monopolized the markets for body-worn camera systems and long-range conducted energy weapons, such as Tasers, through acquiring its largest competitor and signing decade-long non-compete, market allocation, and no-poach agreements with its main competitor.
Rotavirus Antitrust Litigation
Baltimore v. Merck (E.D. Pa.): Cohen Milstein is representing the City of Baltimore in this putative antitrust class action, alleging that Merck’s bundled “loyalty” program for the rotavirus vaccine called RotaTeq is a scheme to leverage and maintain its monopoly in Rotavirus vaccines. As a consequence, Plaintiffs claim that Merck is able to charge customers supercompetitive prices.